### Indication

Gastro-oesophageal reflux disease

**ICD11 code:** DA22.Z

---

### INN

Ranitidine

### Medicine type

Chemical agent

### List type

Core

### Formulations

<table>
<thead>
<tr>
<th>Route</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Liquid</td>
<td>75 mg per 5 mL (as hydrochloride)</td>
</tr>
<tr>
<td>Oral &gt; Solid</td>
<td>150 mg (as hydrochloride)</td>
</tr>
<tr>
<td>Parenteral &gt;</td>
<td>General injections &gt; unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)</td>
</tr>
</tbody>
</table>

### EML status history

- First added in 2003 (TRS 920)
- Changed in 2007 (TRS 950)
- Changed in 2021

### Sex

All

### Age

Also recommended for children

### Therapeutic alternatives

Medicines within the same pharmacological class can be used

### Therapeutic alternatives limitations

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)

### Therapeutic alternatives limitations for EMLc

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)

### Patent information

Patents have expired in most jurisdictions

Read more about patents.

### Wikipedia

Ranitidine

### DrugBank

Ranitidine

---

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, A02BA H2-receptor antagonists (excluding combinations), be specified as therapeutic alternatives under the square box listing for ranitidine on the EML and EMLc.